Figure 2.

Treatment with the CD200 inhibitor extends progression free and overall survival in dogs. Following surgical resection of the tumors, serial vaccinations of autologous tumor lysate and canine-specific CD200AR-L were administered to each dog. Disease status was followed using magnetic resonance imaging (MRI) and calculated progression-free (black line) and overall survival (blue line) times were significantly longer than a cohort of dogs treated with tumor lysate alone after surgery (red line) (p = 0.0001). Ticks represent censored cases because the dog is still alive (n = 3) or had no evidence of disease on postmortem examination of the brain (n = 6).